$299.02 general Payment -- Takeda Pharmaceuticals to Dr. Paul Turner

Payment Details

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Takeda Pharmaceuticals made a $299.02 general payment to Paul Turner, a Rare Disease specialist in City, CO. The payment was associated with Keytruda. Dr. Paul Turner received a $299.02 payment from Takeda Pharmaceuticals on September 18, 2024. The payment was for educational purposes related to Keytruda. This payment falls under the 'general' payment type.

Patient Guidance: What This Payment Means for You

This payment was for educational materials that may help your doctor understand treatments like Keytruda better. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Payments for education in the Rare Disease specialty can vary, but this amount is generally considered low.

Regulatory Context: Sunshine Act Requirements

This payment is reported under the Sunshine Act, requiring disclosure of financial relationships between drug manufacturers and healthcare providers.

Related Topics

This payment is related to the following healthcare transparency topics:

• pharmaceutical-payments
• medical-education
• rare-disease
• oncology-drugs
• physician-payments
• cms-open-payments

Understanding general Payments

general payments are one of several categories of financial transfers from pharmaceutical and medical device companies to physicians that must be reported under the Sunshine Act. Understanding the type and context of a payment is important for evaluating its significance. Not all payments are equal -- a research grant has very different implications than a promotional speaking fee.

Frequently Asked Questions About This Payment

What was this $299.02 payment for?

This was a general payment of $299.02 from Takeda Pharmaceuticals to Paul Turner, categorized as "Education". It was associated with Keytruda. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Paul Turner accept pharmaceutical money?

Yes, Paul Turner received this $299.02 payment from Takeda Pharmaceuticals. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Paul Turner's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this general payment?

A general payment of $299.02 should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Rare Disease?

To compare this payment against Rare Disease averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Rare Disease physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Paul Turner's relationship with Takeda Pharmaceuticals?

The payment amount is relatively small, suggesting a limited scope of educational activity. This $299.02 general payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Rare Disease?

The payment is specifically tied to the drug Keytruda, indicating a focus on a particular therapy.

What should patients do after learning about this payment?

This payment was for educational materials that may help your doctor understand treatments like Keytruda better.

What else should I know about this general payment?

The date of payment is recent, falling within the current reporting period.

Related Reports

• View Dr. Paul Turner's full payment report
• Takeda Pharmaceuticals full spending report
• Browse all Rare Disease payments
• Browse all payments in Colorado
• Search for other payments